Loading clinical trials...

COMPLETEDPhase 1NCT00623870

A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms. ...

Lead sponsor: Hoffmann-La Roche•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

NCT07162038 · Hematologic Malignancies, Hematologic Neoplasms

RECRUITING

Prospective Validation of the OHI Index

NCT05882175 · HLH, Hemophagocytic Lymphohistiocytoses, and more

RECRUITING

UWCCC Molecular Tumor Board Registry

NCT03023202 · Hematologic Neoplasms, Solid Neoplasm

RECRUITING

The ACC Preclinical Research Platform for Precision Oncology

NCT06339541 · Solid Tumor, Hematologic Neoplasms

Active Not RecruitingPhase 1/2

Optimizing PTCy Dose and Timing

NCT03983850 · Graft Versus Host Disease, Hematologic Neoplasms

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 2, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment116

Start dateMay 2008

Last updatedNov 2, 2016

Condition

Hematologic Neoplasms

Locations shown

Duarte, California

New Brunswick, New Jersey

New York, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 2, 2016Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Prospective Validation of the OHI Index

UWCCC Molecular Tumor Board Registry

The ACC Preclinical Research Platform for Precision Oncology

Optimizing PTCy Dose and Timing

Trial snapshot

Condition

Locations shown

For caregivers